Trial · NCT00429273

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273, Phase 4, Completed, University of California, Los Angeles; results first posted 2017-06-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder. Trials, record NCT00429273. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00429273

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
NCT number: NCT00429273
Status: Completed
Phases: Phase 4
Enrollment: 212 participants, actual
Lead sponsor: University of California, Los Angeles
Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Guanfacine, Methylphenidate (MPH)
First posted: 2007-01-31
Last updated: 2021-07-30
Results first posted: 2017-06-14
Limitations and caveats: Larger group sizes would enable more conclusive tests of treatment differences; Study design began with guanfacine first and addition of a stimulant second, making difficult to compare to those study designs adding guanfacine to ongoing stimulants.

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Measured at baseline Week 4 and Week 8	The primary clinical efficacy variable for treatment was the ADHD-RS-IV (Attention-Deficit/Hyperactivity Disorder Rating Scale) Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ). The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3). Min 0; max 3. Scores are obtained by summing each item; The higher the score, the worse the outcome. Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Measured at baseline Week 4 and Week 8	Every contrast includes estimates of maturation/time trend and the within subject covariance structure based on all participants using full information maximum likelihood estimation.	units on a scale	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Guan and Placebo	Total ADHD-RS Score	-7.77	Standard Error 1.70	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between DMPH and Placebo	Total ADHD-RS Score	-7.99	Standard Error 1.22	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Placebo and Combo	Total ADHD-RS Score	-10.66	Standard Error 1.99	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Guan and Placebo	Inattentive Subscale	-4.14	Standard Error 0.99	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between DMPH and Placebo	Inattentive Subscale	-4.10	Standard Error 0.71	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Placebo and Combo	Inattentive Subscale	-5.89	Standard Error 1.15	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Guan and Placebo	Hyperactive Impulsive Subscale	-3.73	Standard Error 0.92	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between DMPH and Placebo	Hyperactive Impulsive Subscale	-4.0	Standard Error 0.69	units on a scale
ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)	Estimated Difference Between Placebo and Combo	Hyperactive Impulsive Subscale	-5.10	Standard Error 1.12	units on a scale

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Group 1: Guan-Guan+Placebo	68
Overall Study	STARTED	Group 2: Placebo-Placebo+DMPH	69
Overall Study	STARTED	Group 3: Guan-Guan+DMPH	70
Overall Study	COMPLETED	Group 1: Guan-Guan+Placebo	60
Overall Study	COMPLETED	Group 2: Placebo-Placebo+DMPH	61
Overall Study	COMPLETED	Group 3: Guan-Guan+DMPH	61
Overall Study	NOT COMPLETED	Group 1: Guan-Guan+Placebo	8
Overall Study	NOT COMPLETED	Group 2: Placebo-Placebo+DMPH	8
Overall Study	NOT COMPLETED	Group 3: Guan-Guan+DMPH	9

Source ClinicalTrials.gov

Adverse events36

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal Pain Upper	Gastrointestinal disorders	Group 1: Guan-Guan+Placebo	11	68	11
other	Abdominal Pain Upper	Gastrointestinal disorders	Group 2: Placebo-Placebo+DMPH	10	69	10
other	Abdominal Pain Upper	Gastrointestinal disorders	Group 3: Guan-Guan+DMPH	10	70	10
other	Abdominal Pain	Gastrointestinal disorders	Group 1: Guan-Guan+Placebo	19	68	19
other	Abdominal Pain	Gastrointestinal disorders	Group 2: Placebo-Placebo+DMPH	18	69	18
other	Abdominal Pain	Gastrointestinal disorders	Group 3: Guan-Guan+DMPH	16	70	16
other	Headache	Psychiatric disorders	Group 1: Guan-Guan+Placebo	34	68	34
other	Headache	Psychiatric disorders	Group 2: Placebo-Placebo+DMPH	23	69	23
other	Headache	Psychiatric disorders	Group 3: Guan-Guan+DMPH	23	70	23
other	Irritability	Psychiatric disorders	Group 1: Guan-Guan+Placebo	15	68	15

1 to 10 of 36Source ClinicalTrials.gov

See all 36 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Group 1: Guan-Guan+Placebo	0	68
Total, all-cause mortality	Group 2: Placebo-Placebo+DMPH	0	69
Total, all-cause mortality	Group 3: Guan-Guan+DMPH	0	70
Total, other adverse events	Group 1: Guan-Guan+Placebo	66	68
Total, other adverse events	Group 2: Placebo-Placebo+DMPH	66	69
Total, other adverse events	Group 3: Guan-Guan+DMPH	69	70
Total, serious adverse events	Group 1: Guan-Guan+Placebo	0	68
Total, serious adverse events	Group 2: Placebo-Placebo+DMPH	0	69
Total, serious adverse events	Group 3: Guan-Guan+DMPH	0	70

Source ClinicalTrials.gov

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
27453079	DERIVED	PubMed
27453080	DERIVED	PubMed
27453081	DERIVED	PubMed
27483130	DERIVED	PubMed
35963558	DERIVED	PubMed
35963559	DERIVED	PubMed
36971690	DERIVED	PubMed
41342306	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P50MH077248	CIDAR: Translational Research to Enhance Cognitive Control (TRECC)	MCCRACKEN, JAMES T.	UNIVERSITY OF CALIFORNIA LOS ANGELES	NATIONAL INSTITUTE OF MENTAL HEALTH	2006 to 2011

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00429273

GET https://conductscience.org/api/trials/v1/NCT00429273/events?page=2

API reference For AI assistants